Tuesday April 4, 2017 0 comments
TANOVEA-CA1 was recently granted conditional approval by the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM), making TANOVEA-CA1 the first and only new animal drug indicated for the treatment of lymphoma in dogs, the company said.
“VetDC stands out among an elite group of pure-play animal health startups that have advanced a novel program from development through commercialization,” said Dr. Terry Opgenorth, VP of CSU Ventures and VetDC co-founder.
“We believe TANOVEA-CA1 represents a significant breakthrough in the rapidly evolving field of veterinary oncology.”
“We are ecstatic to hear the news of TANOVEA-CA1’s commercial availability,” said Dr. Craig Clifford, a board-certified veterinary oncologist and clinical investigator at Hope Veterinary Specialists in Malvern, PA.
“Based on our first-hand experience as part of a robust clinical trials program, we believe TANOVEA-CA1 has the potential to become a cornerstone for the treatment of lymphoma in dogs.”
VetDC said TANOVEA-CA1 (rabacfosadine for injection) is a novel small molecule drug designed to preferentially target and attack rapidly dividing cancer cells implicated in lymphoma.
TANOVEA-CA1 has demonstrated anti-tumor activity in both naïve and relapsed canine lymphoma cases, with a generally well-tolerated safety profile, the company said.
TANOVEA-CA1 is administered intravenously every three weeks for up to five doses.
VetDC said TANOVEA-CA1 is conditionally approved by the FDA for the treatment of canine lymphoma pending a full demonstration of effectiveness.
For additional prescribing, safety and ordering information, visit tanovea.com.